Abstract Components of the complement system and atypical parameters of coagulation were reported in COVID-19 patients, as well as the exacerbation of the inflammation and coagulation activity. Mannose binding lectin (MBL)- associated serine proteases (MASPs) play an important role in viral recognition and subsequent activation of the lectin pathway of the complement system and blood coagulation, connecting both processes. Genetic variants of MASP1 and MASP2 genes are further associated with different levels and functional efficiency of their encoded proteins, modulating susceptibility and severity to diseases. Our review highlights the possible role of MASPs in SARS-COV-2 binding and activation of the lectin pathway and blood coagulation cascades, as well as their associations with comorbidities of COVID-19. MASP-1 and/or MASP-2 present an increased expression in patients with COVID-19 risk factors: diabetes, arterial hypertension and cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, and cerebrovascular disease. Based also on the positive results of COVID-19 patients with anti-MASP-2 antibody, we propose the use of MASPs as a possible biomarker of the progression of COVID-19 and the investigation of new treatment strategies taking into consideration the dual role of MASPs, including MASP inhibitors as promising therapeutic targets against COVID-19.

中文翻译：

---

MASP 处于补体和凝血级联之间的十字路口 - 以 COVID-19 为例

摘要 据报道，COVID-19 患者的补体系统组成和凝血参数不典型，以及炎症和凝血活性的恶化。甘露糖结合凝集素 (MBL) 相关丝氨酸蛋白酶 (MASP) 在病毒识别和随后补体系统凝集素途径的激活以及血液凝固中发挥重要作用，将这两个过程连接起来。MASP1 和 MASP2 基因的遗传变异进一步与其编码蛋白的不同水平和功能效率相关，从而调节疾病的易感性和严重程度。我们的综述强调了 MASP 在 SARS-COV-2 结合、凝集素途径和凝血级联激活中的可能作用，以及它们与 COVID-19 合并症的关联。MASP-1 和/或 MASP-2 在患有 COVID-19 危险因素的患者中表达增加：糖尿病、高血压和心血管疾病、慢性肾脏疾病、慢性阻塞性肺疾病和脑血管疾病。同样基于 COVID-19 患者抗 MASP-2 抗体的阳性结果，我们建议使用 MASP 作为 COVID-19 进展的可能生物标志物，并考虑到新的治疗策略的双重作用进行研究MASP，包括 MASP 抑制剂，是有前景的 COVID-19 治疗靶点。